Prostate Cancer Awareness Month September 2019 - US TOO SEA Blue Event - Alicia Morgans

Brenda Martone invites Alicia Morgans to share details on the upcoming Prostate Cancer Awareness Month event in Chicago, put on by Us TOO International, the 15th Annual SEA Blue Chicago Prostate Cancer Walk and Run. SEA Blue is a celebration of life, of those who have risen to the challenge to fight prostate cancer, of the lives that have been lost to the disease, and of the people we will help to...

The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin

Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...

TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal

Petros Grivas invites Neeraj Agarwal to discuss the TITAN trial which reported the first interim analysis at ASCO 2019. The TITAN trial is a "Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With metastatic hormone-sensitive prostate cancer (mHSPC). A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The...

Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris

Kim Chi, MD discusses the first results from TITAN, A phase 3 randomized, placebo-controlled, double-blind study of apalutamide (APA) versus placebo (PBO) in men with metastatic hormone-sensitive prostate cancer (mHSPC), with Michael Morris, MD, and Alicia Morgans, MD. TITAN was designed to accrue patients with prior treatment for localized prostate cancer or prior docetaxel for mHSPC were allowed...

Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin

Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...

Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans

Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers 3 main topics including systemic therapies, treatment of the primary and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy and ultimately cure, especially when...

Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans

Alicia Morgans presents a lecture on the contemporary management strategies for hormone sensitive prostate cancer with a focus on systemic therapy including chemohormonal approaches and the use of abiraterone for metastatic hormone sensitive disease. In the discussion, Alicia compares and contrasts both the CHAARTED and STAMPEDE data and provides an update on treatment today, including evidence ba...

Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans

Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...

The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke

Leanne Schimke begins her presentation discussing the role of the nurse practitioner in the treatment of patients with advanced prostate cancer. She first looks at newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) patients. Also, presented is treatment options for mHSPC and the administration, adverse effects, nursing considerations, and drug interactions of these treatments. Bi...

Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans

Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.